These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15102561)

  • 41. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
    Murray TJ
    Expert Opin Drug Saf; 2006 Mar; 5(2):265-74. PubMed ID: 16503747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 44. The current role of mitoxantrone in the treatment of multiple sclerosis.
    Cocco E; Marrosu MG
    Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of mitoxantrone for the treatment of multiple sclerosis.
    Jain KK
    Expert Opin Investig Drugs; 2000 May; 9(5):1139-49. PubMed ID: 11060734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
    Neuhaus O; Kieseier BC; Hartung HP
    Expert Rev Neurother; 2004 Jan; 4(1):17-26. PubMed ID: 15853611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitoxantrone immunotherapy in multiple sclerosis.
    Gonsette RE
    Mult Scler; 1996 Jul; 1(6):329-32. PubMed ID: 9345411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
    Gonsette RE; Dubois B
    J Neurol Sci; 2004 Aug; 223(1):81-6. PubMed ID: 15261566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunologic therapy for relapsing-remitting multiple sclerosis.
    MacLean HJ; Freedman MS
    Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
    Noseworthy JH
    Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
    [No Abstract]   [Full Text] [Related]  

  • 54. [New therapeutic strategies in multiple sclerosis].
    Berger E; Rumbach L
    Rev Med Interne; 1999 Aug; 20 Suppl 3():346s-350s. PubMed ID: 10480185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel therapeutic options for multiple sclerosis.
    Curtin F; Hartung HP
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
    Stüve O; Kita M; Pelletier D; Fox RJ; Stone J; Goodkin DE; Zamvil SS
    Mult Scler; 2004 Jun; 10 Suppl 1():S58-61. PubMed ID: 15218811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
    Donoghue S; Greenlees C
    Expert Opin Investig Drugs; 2000 Jan; 9(1):167-71. PubMed ID: 11060669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Arnason BG; Coyle PK; Frohman EM; Paty DW;
    Neurology; 2003 Nov; 61(10):1332-8. PubMed ID: 14638950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.